financetom
Business
financetom
/
Business
/
EV maker Polestar pauses annual forecast amid tariff uncertainty
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EV maker Polestar pauses annual forecast amid tariff uncertainty
May 25, 2025 9:52 PM

(Reuters) -Polestar paused its 2025 forecast on Wednesday as the electric-vehicle maker braces for a potential hit from sweeping U.S. tariffs that threaten to roil supply chains and push up car prices.

The Swedish company reported strong first-quarter sales earlier this month, but CEO Michael Lohscheller warned of a hit from American import duties as it looks to shift manufacturing to the U.S. and Europe to cut reliance on China.

U.S. President Donald Trump's rapidly changing trade policy and levies of at least 145% on China have forced many automakers, including Stellantis, General Motors and Volvo Cars, to pull their forecasts and several others to warn of profit and revenue hits.

In response to industry pushback, Trump on Tuesday signed an executive order to soften the blow of his auto tariffs by mixing credits with relief from other levies on parts and materials.

Polestar continues to expect compounded growth in vehicles sold between 30% and 35% for this and the next two years as well as an improvement in gross margin through 2025.

Its discounts targeting disgruntled Tesla owners have helped the company drum up demand in the U.S. even as worries of a possible recession due to the tariffs weigh on consumer spending.

ANOTHER DELAY

Polestar said it has filed a notice with the U.S. Securities and Exchange Commission to delay the publication of its 2024 annual report. It now expects to file the document before or on May 14.

The company was expected to report its already delayed fourth-quarter results in March, but that got pushed to April, leaving investors to question its accounting measures.

Polestar's delay in publishing its fourth-quarter results follows previous issues with its financial disclosures, having to republish statements from past financial years due to errors.

The company expects to report first-quarter results in May.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Apple refused permission to appeal UK ruling on app store commissions
Apple refused permission to appeal UK ruling on app store commissions
Nov 13, 2025
LONDON (Reuters) -Apple ( AAPL ) was on Thursday refused permission to appeal against a London tribunal ruling that it abused its dominant position by charging app developers unfair commissions. The Competition Appeal Tribunal (CAT) ruled against Apple ( AAPL ) last month after a trial, finding Apple ( AAPL ) had abused its dominant position by shutting out competition...
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: BALYASNY ASSET MANAGEMENT L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Why Canadian Solar's Stock Is Soaring Despite Posting Another Quarterly Loss
Why Canadian Solar's Stock Is Soaring Despite Posting Another Quarterly Loss
Nov 13, 2025
Canadian Solar Inc. ( CSIQ ) stock soared after delivering third-quarter 2025 net revenues of $1.487 billion, beating the $1.366 billion estimate, even as its adjusted loss of 58 cents per diluted share missed the expected 53-cent loss. Revenue slipped 12% sequentially and 1% year over year. Gross margin rose to 17.2%, above guidance and up from 16.4% a year...
Metsera shareholders vote for up to $10 billion acquisition by Pfizer
Metsera shareholders vote for up to $10 billion acquisition by Pfizer
Nov 13, 2025
(Reuters) -Metsera ( MTSR ) shareholders on Thursday approved Pfizer's ( PFE ) takeover offer worth up to $10 billion, as per preliminary count, allowing the U.S. pharmaceutical giant to gain a foothold in the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk. The approval paves the way for Pfizer ( PFE ) to diversify...
Copyright 2023-2026 - www.financetom.com All Rights Reserved